(from left) Anna Saborowski, Gajanan Kendre and Arndt Vogel in a laboratory of the MHH Department of Gastroenterology with violet-stained bile duct tumour cells. Copyright: Karin Kaiser / MHH.
( from left ) Anna Saborowski, Gajanan Kendre and Arndt Vogel in a laboratory of the MHH Department of Gastroenterology with violet-stained bile duct tumour cells. Copyright: Karin Kaiser / MHH. MHH research team investigates molecular biomarkers for individualised tumour therapy. Status: 30 March 2021 Intrahepatic cholangiocarcinoma (ICC) develops within the liver. With one to two cases per 100,000 inhabitants in Germany, ICC is one of the rare diseases overall, but it is the second most common liver cancer. The aggressive bile duct tumour remains clinically inconspicuous for a long time, so that it is often only detected late. Because the tumour also only responds to chemotherapy to a limited extent, those affected often have a poor prognosis.
UM DIESEN ARTIKEL ZU LESEN, ERSTELLEN SIE IHR KONTO
Und verlängern Sie Ihre Lektüre, kostenlos und unverbindlich.
